Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D

Yumiko Ohkubo, Akihito Ueta, Tetsuya Ito, Satoshi Sumi, Mari Yamada, Katsuko Ozawa, Hajime Togari

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Ornithine aminotransferase (OAT) deficiency (MIM: 258870) is a rare congenital metabolic disorder characterized by gyrate atrophy of the choroid and retina. Here, we report a 37-year-old male with gyrate atrophy of the choroid and retina who has been treated for 18 years. At the age of 7 years, the patient consulted an ophthalmologist due to progressive loss of vision. A large atrophied area was observed in his retina, and OAT deficiency was suspected. At the age of 19 years, amino acid analysis revealed high serum ornithine levels (1140 nmol/ml), with the normal range being 40-100 nmol/ml. He was treated with vitamin B6 300 mg/day for 6 months, which successfully reduced his serum ornithine levels by 20-30%. For 18 years since, his serum ornithine levels have been maintained with vitamin B6 medication. There was no further impairment of vision or increase in the atrophied area, as judged by ophthalmoscopic examination. OAT activity was undetected in white blood cells of the patient and was 105% and 45% of normal values in his wife and son, respectively. OAT gene analysis revealed a novel mutation of Gly237Asp in exon 7 (710G > A) in both alleles of the patient, while his son was a heterozygote for the mutation. Notably, this novel mutation is associated with a vitamin B6-responsive phenotype. Therefore, early diagnosis and treatment with vitamin B6 may prevent loss of vision in some patients with OAT deficiency.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalTohoku Journal of Experimental Medicine
Volume205
Issue number4
DOIs
Publication statusPublished - 01-04-2005
Externally publishedYes

Fingerprint

Gyrate Atrophy
Ornithine-Oxo-Acid Transaminase
Vitamin B 6
Ornithine
Mutation
Nuclear Family
Reference Values
Serum
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Heterozygote
Spouses
Retina
Early Diagnosis
Exons
Leukocytes
Blood
Genes
Alleles
Cells
Phenotype

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ohkubo, Yumiko ; Ueta, Akihito ; Ito, Tetsuya ; Sumi, Satoshi ; Yamada, Mari ; Ozawa, Katsuko ; Togari, Hajime. / Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D. In: Tohoku Journal of Experimental Medicine. 2005 ; Vol. 205, No. 4. pp. 335-342.
@article{a79edc688ff84f8e95aa66743ff36d16,
title = "Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D",
abstract = "Ornithine aminotransferase (OAT) deficiency (MIM: 258870) is a rare congenital metabolic disorder characterized by gyrate atrophy of the choroid and retina. Here, we report a 37-year-old male with gyrate atrophy of the choroid and retina who has been treated for 18 years. At the age of 7 years, the patient consulted an ophthalmologist due to progressive loss of vision. A large atrophied area was observed in his retina, and OAT deficiency was suspected. At the age of 19 years, amino acid analysis revealed high serum ornithine levels (1140 nmol/ml), with the normal range being 40-100 nmol/ml. He was treated with vitamin B6 300 mg/day for 6 months, which successfully reduced his serum ornithine levels by 20-30{\%}. For 18 years since, his serum ornithine levels have been maintained with vitamin B6 medication. There was no further impairment of vision or increase in the atrophied area, as judged by ophthalmoscopic examination. OAT activity was undetected in white blood cells of the patient and was 105{\%} and 45{\%} of normal values in his wife and son, respectively. OAT gene analysis revealed a novel mutation of Gly237Asp in exon 7 (710G > A) in both alleles of the patient, while his son was a heterozygote for the mutation. Notably, this novel mutation is associated with a vitamin B6-responsive phenotype. Therefore, early diagnosis and treatment with vitamin B6 may prevent loss of vision in some patients with OAT deficiency.",
author = "Yumiko Ohkubo and Akihito Ueta and Tetsuya Ito and Satoshi Sumi and Mari Yamada and Katsuko Ozawa and Hajime Togari",
year = "2005",
month = "4",
day = "1",
doi = "10.1620/tjem.205.335",
language = "English",
volume = "205",
pages = "335--342",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "4",

}

Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D. / Ohkubo, Yumiko; Ueta, Akihito; Ito, Tetsuya; Sumi, Satoshi; Yamada, Mari; Ozawa, Katsuko; Togari, Hajime.

In: Tohoku Journal of Experimental Medicine, Vol. 205, No. 4, 01.04.2005, p. 335-342.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D

AU - Ohkubo, Yumiko

AU - Ueta, Akihito

AU - Ito, Tetsuya

AU - Sumi, Satoshi

AU - Yamada, Mari

AU - Ozawa, Katsuko

AU - Togari, Hajime

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Ornithine aminotransferase (OAT) deficiency (MIM: 258870) is a rare congenital metabolic disorder characterized by gyrate atrophy of the choroid and retina. Here, we report a 37-year-old male with gyrate atrophy of the choroid and retina who has been treated for 18 years. At the age of 7 years, the patient consulted an ophthalmologist due to progressive loss of vision. A large atrophied area was observed in his retina, and OAT deficiency was suspected. At the age of 19 years, amino acid analysis revealed high serum ornithine levels (1140 nmol/ml), with the normal range being 40-100 nmol/ml. He was treated with vitamin B6 300 mg/day for 6 months, which successfully reduced his serum ornithine levels by 20-30%. For 18 years since, his serum ornithine levels have been maintained with vitamin B6 medication. There was no further impairment of vision or increase in the atrophied area, as judged by ophthalmoscopic examination. OAT activity was undetected in white blood cells of the patient and was 105% and 45% of normal values in his wife and son, respectively. OAT gene analysis revealed a novel mutation of Gly237Asp in exon 7 (710G > A) in both alleles of the patient, while his son was a heterozygote for the mutation. Notably, this novel mutation is associated with a vitamin B6-responsive phenotype. Therefore, early diagnosis and treatment with vitamin B6 may prevent loss of vision in some patients with OAT deficiency.

AB - Ornithine aminotransferase (OAT) deficiency (MIM: 258870) is a rare congenital metabolic disorder characterized by gyrate atrophy of the choroid and retina. Here, we report a 37-year-old male with gyrate atrophy of the choroid and retina who has been treated for 18 years. At the age of 7 years, the patient consulted an ophthalmologist due to progressive loss of vision. A large atrophied area was observed in his retina, and OAT deficiency was suspected. At the age of 19 years, amino acid analysis revealed high serum ornithine levels (1140 nmol/ml), with the normal range being 40-100 nmol/ml. He was treated with vitamin B6 300 mg/day for 6 months, which successfully reduced his serum ornithine levels by 20-30%. For 18 years since, his serum ornithine levels have been maintained with vitamin B6 medication. There was no further impairment of vision or increase in the atrophied area, as judged by ophthalmoscopic examination. OAT activity was undetected in white blood cells of the patient and was 105% and 45% of normal values in his wife and son, respectively. OAT gene analysis revealed a novel mutation of Gly237Asp in exon 7 (710G > A) in both alleles of the patient, while his son was a heterozygote for the mutation. Notably, this novel mutation is associated with a vitamin B6-responsive phenotype. Therefore, early diagnosis and treatment with vitamin B6 may prevent loss of vision in some patients with OAT deficiency.

UR - http://www.scopus.com/inward/record.url?scp=17844410686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844410686&partnerID=8YFLogxK

U2 - 10.1620/tjem.205.335

DO - 10.1620/tjem.205.335

M3 - Article

C2 - 15750329

AN - SCOPUS:17844410686

VL - 205

SP - 335

EP - 342

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 4

ER -